Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a220b8523dc1addf

Jump to content

Talk:DLL3

Page contents not supported in other languages.
Add topic
From Wikipedia, the free encyclopedia

Possible target for small-cell lung cancer (SCLC)

[edit]

Expert Examines Immunotherapy Potential in Small Cell Lung Cancer says "DLL3 is a molecule that is expressed on about two-thirds of SCLCs, and it is actually a functionally active molecule. It’s a NOTCHED ligand that inhibits NOTCH1. That activates CO1, which is a main driver of SCLC. Therefore, Stemcentrx linked a drug to an antibody against DLL3 with a chemotherapy drug and showed that there was a high response rate in the second- and third-line setting of SCLC." rovalpituzumab tesirine - Rod57 (talk) 14:25, 19 May 2016 (UTC)Reply